382 related articles for article (PubMed ID: 33256899)
1. Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020.
Rank CU; Schmiegelow K
Semin Hematol; 2020 Jul; 57(3):102-114. PubMed ID: 33256899
[TBL] [Abstract][Full Text] [Related]
2. Should immunologic strategies be incorporated into frontline ALL therapy?
Rank CU; Stock W
Best Pract Res Clin Haematol; 2018 Dec; 31(4):367-372. PubMed ID: 30466749
[TBL] [Abstract][Full Text] [Related]
3. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia.
Uy N; Nadeau M; Stahl M; Zeidan AM
J Blood Med; 2018; 9():67-74. PubMed ID: 29713210
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the treatment of acute lymphoblastic leukemia.
Rafei H; Kantarjian HM; Jabbour EJ
Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
[TBL] [Abstract][Full Text] [Related]
5. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Frey NV; Luger SM
Blood; 2015 Jul; 126(5):589-96. PubMed ID: 25966988
[TBL] [Abstract][Full Text] [Related]
6. New approaches to the treatment of older adults with acute lymphoblastic leukemia.
Schwartz M; Wieduwilt MJ
Semin Hematol; 2020 Jul; 57(3):122-129. PubMed ID: 33256901
[TBL] [Abstract][Full Text] [Related]
7. Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia.
Conde-Royo D; Juárez-Salcedo LM; Dalia S
Drugs Context; 2020; 9():. PubMed ID: 33110433
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Acute Lymphoblastic Leukemia in Adults: Applying Lessons Learned in Children.
Aldoss IT; Marcucci G; Pullarkat V
Oncology (Williston Park); 2016 Dec; 30(12):1080-91. PubMed ID: 27987201
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy approaches to treat adult acute lymphoblastic leukemia.
Maino E; Bonifacio M; Scattolin AM; Bassan R
Expert Rev Hematol; 2016 Jun; 9(6):563-77. PubMed ID: 27011303
[TBL] [Abstract][Full Text] [Related]
10. Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.
Jabbour E; Pui CH; Kantarjian H
JAMA Oncol; 2018 Oct; 4(10):1413-1420. PubMed ID: 29931220
[TBL] [Abstract][Full Text] [Related]
11. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
[TBL] [Abstract][Full Text] [Related]
12. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past.
Short NJ; Kantarjian H
Lancet Haematol; 2023 May; 10(5):e382-e388. PubMed ID: 37003279
[TBL] [Abstract][Full Text] [Related]
13. [ALL in adult patients: Contribution and limits of pediatric management].
Rabian F; Boissel N
Bull Cancer; 2021 Feb; 108(2):187-197. PubMed ID: 32981690
[TBL] [Abstract][Full Text] [Related]
14. Therapy of Relapsed/Refractory Acute Lymphoblastic Leukemia Today and Tomorrow.
Hrabovský Š; Folber F; Doubek M
Klin Onkol; 2019; 32(2):90-96. PubMed ID: 30995847
[TBL] [Abstract][Full Text] [Related]
15. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
Rambaldi A; Ribera JM; Kantarjian HM; Dombret H; Ottmann OG; Stein AS; Tuglus CA; Zhao X; Kim C; Martinelli G
Cancer; 2020 Jan; 126(2):304-310. PubMed ID: 31626339
[TBL] [Abstract][Full Text] [Related]
16. Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia.
Wei G; Wang J; Huang H; Zhao Y
J Hematol Oncol; 2017 Aug; 10(1):150. PubMed ID: 28821272
[TBL] [Abstract][Full Text] [Related]
17. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia.
Liu D; Zhao J; Song Y; Luo X; Yang T
J Hematol Oncol; 2019 Feb; 12(1):15. PubMed ID: 30736842
[TBL] [Abstract][Full Text] [Related]
19. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.
Short NJ; Kantarjian H; Jabbour E
Leukemia; 2021 Nov; 35(11):3044-3058. PubMed ID: 34172894
[TBL] [Abstract][Full Text] [Related]
20. Innovative Approaches to the Management of Acute Lymphoblastic Leukemia Across the Age Spectrum.
Curran E; Muffly L; Luskin MR
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-11. PubMed ID: 35503981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]